Main Reasons for the Market Growth are the Growing Recognition of Precision Medicine
The increasing number of multidrug-resistant organisms and increased awareness of precision medicine are the primary factors driving market expansion. Every year, more than 2.8 million antibiotic-resistant infections occur in the United States, according to the Centres for Disease Control and Prevention (CDC). In accordance with the European Centre for Disease Prevention and Control (ECDC), 30-50% of all antibiotics provided to human patients are unnecessary and antibiotic overuse promotes resistance. Rising awareness programmes and initiatives for personalised medicine have a positive effect on market growth, and another factor that is playing a critical role in propelling the antimicrobial susceptibility testing market forward is increased use of the tests by pharmaceutical companies. For instance, in February 2024, it was announced that positive headline results were obtained from the pivotal EAGLE-1 phase III trial for gepotidacin, an innovative oral antibiotic with a unique mechanism of action for treating uncomplicated urogenital gonorrhoea in adolescents and adults. The primary efficacy goal was achieved in the trial, showing that gepotidacin (administered orally in two doses of 3,000mg) was as effective as the combination of intramuscular (IM) ceftriaxone (500mg) and oral azithromycin (1,000mg), a well-known treatment for gonorrhoea. The outcome is determined by the success or failure of the microbiological response at the Test-of-Cure (ToC) visit occurring 3-7 days post treatment.
Antimicrobial Susceptibility Tests Are Gaining Popularity as A Result of The Increasing Prevalence of Infectious Diseases
The surge in global travel trends, along with undeveloped healthcare infrastructure in developing countries, is contributing to the emergence of various infectious diseases. Newer variants and older diseases are emerging at faster rates. People all across the world are travelling to unknown and farthest regions, exposing themselves to new diseases. This enhances the demand for rapid medication development, fuelling the expansion of the antimicrobial susceptibility testing market. Other factors include a lack of basic hygiene and sanitation, among others. Furthermore, new product releases by leading market competitors, as well as an increase in the number of R&D activities, are driving market revenue growth. For instance, in July 2024, Shinogi introduced the in vitro diagnostic product "Shionogi MIC Dry Plate Cefiderocol" on July 8, 2024, to assess sensitivity to treatment for gram-negative bacterial infections. This improvement in the drug-sensitivity testing system is anticipated to help increase the proper utilization of Fetroja.
Recent Trends in Antimicrobial Susceptibility Test Market
- The rising occurrence of antibiotic-resistant bacteria is fuelling the need.
- Personalized medicine is driving the advancement of customized antimicrobial treatments.
- Enhanced monitoring of antimicrobial resistance trends leading to better results for patients.
- Growing funding from both governments and private companies in research and development.
- Rising knowledge and educational campaigns regarding antimicrobial resistance.
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs…!
Complex Regulatory Frameworks and the High Cost of Automated Laboratory Instruments are Likely to Pose Challenges
One of the most significant challenges with antibiotic susceptibility testing is the time lag between identifying clinical breakpoints, approving novel antimicrobial medications and placing these medications on the market. The FDA establishes cut off criteria when pharmaceutical firms submit unapproved new drug applications. The lack of clinical breakpoints for many drugs further limits the adoption of antimicrobial susceptibility solutions. For instance, there are currently no clinical cut-offs for determining antifungal treatment effectiveness in invasive non-Aspergillus mould infections. Automated antimicrobial laboratory equipment is expensive and offers modern features and functionalities. The adoption of automated AST systems reduces incubation and detection times. Another barrier to this industry's growth is the high cost of maintenance for these advanced devices that require regular care and are loaded with cutting-edge software. The lack of standardisation and comparability of AST is an important barrier to market revenue development.
Partnerships and Collaborations are Playing a Pivotal Role in Advancing the Antimicrobial Susceptibility Test Market
Partnerships and collaborations are crucial in driving progress in the antimicrobial market. Companies and research institutions are speeding up the development and market introduction of new antimicrobial solutions by combining resources, expertise, and technology. These partnerships are vital for addressing the increasing problem of antibiotic resistance by facilitating the exchange of information and the incorporation of advanced technologies. For instance, in June 2024, Eli Lilly and Company revealed a partnership with OpenAI to use OpenAI's generative AI in the development of new antimicrobials for drug-resistant pathogens. Antimicrobial resistance (AMR) poses a major threat to public health and development worldwide. This partnership with OpenAI marks a significant advancement in combating the increasingly ignored issue of antimicrobial resistance. Additionally, the partnership between GARDP and GDF intends to tackle a key problem in the battle against antimicrobial resistance and Low-income countries facing severe drug-resistant infections lack access to new antibiotics and in those countries, even if the drugs are accessible, they are mostly too expensive.
Know Your Competitors and Strengthen Market Share Effectively
Robust Initiatives by Government along with Collaborations in Research Encourage the Regional Market
North America is anticipated to lead the global antimicrobial susceptibility testing market over the forecast period. This is attributed to factors such as the increasing prevalence of antibiotic-resistant infections and increased antibiotic use in the region. Well-established precision medicine and antimicrobial testing awareness programs, positive government initiatives, with an increase in the number of research collaborations are some of the factors projected to fuel market expansion. For instance, in March 2024, U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) partners to work together on creating dashboards for antimicrobial resistance (AMR). These dashboards offer essential information for addressing AMR, which is a rising issue in global health. APHIS will allocate a maximum of US$3 million for these initiatives.
Searching for a Country or Region-Specific Report?
Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost
The report provides a detailed overview of the antimicrobial susceptibility test market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for antimicrobial susceptibility test market has been offered for all regional market share, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the antimicrobial susceptibility test market. These Y-o-Y projections on regional and country-level markets brighten the political, economic and business environment outlook, which are anticipated to have a substantial impact on the growth of the antimicrobial susceptibility test market. Some key country and region included in the antimicrobial susceptibility test market report as follows:
| Regions | Countries |
|---|---|
| North America | United States, Canada |
| Latin America | Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America |
| Europe | Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe |
| Asia Pacific | China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific |
| Middle East and Africa | GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA |
Antimicrobial Susceptibility Test Market Research Report Covers In-depth Analysis on:
- Antimicrobial susceptibility test market detailed segments and segment-wise market breakdown
- Antimicrobial susceptibility test market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in antimicrobial susceptibility test industry)
- Current, historical and forthcoming 10 years market valuation in terms of antimicrobial susceptibility test market size (US$ Mn), share (%), Y-o-Y growth rate, CAGR (%) analysis
- Antimicrobial susceptibility test market demand analysis
- Antimicrobial susceptibility test market regional insights with region-wise market breakdown
- Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
- Latest developments and innovations in antimicrobial susceptibility test market
- Regulatory landscape by key regions and key countries
- Antimicrobial susceptibility test market sales and distribution strategies
- A comprehensive overview of parent market
- A detailed viewpoint on antimicrobial susceptibility test market forecast by countries
- Mergers and acquisitions in antimicrobial susceptibility test market
- Essential information to enhance market position
- Robust research methodology
- Frequently Asked Questions -
What factors are driving growth in the antimicrobial susceptibility test market?
Key drivers include rising antibiotic resistance, increasing prevalence of infectious diseases and the growing demand for personalized medicine in clinical settings.
How does the report help stakeholders in the antimicrobial susceptibility test market?
The report provides comprehensive insights, including market trends, competitive analysis and forecasts, enabling stakeholders to make informed decisions for strategic planning and investment.
What challenges does the antimicrobial susceptibility test market face?
The market faces challenges such as regulatory hurdles, the high cost of advanced testing technologies and the need for continuous updates to testing protocols to keep pace with evolving pathogens.
